Effect of puerarin injection on antioxidant capacity of patients with viral myocarditis

Objective To study the effect of puerarin injection on the antioxidant capacity of patients with viral myocarditis (VMC). Methods Seventy-four patients with VMC who were admitted during the period from January 2014 to March 2017 were randomly divided into the observation group and the control group, 37 cases in each group. The control group was given routine treatment, and on this basis, the observation group was additionally treated with intravenous infusion of puerarin injection. The curative effect and safety were evaluated after 14 days of intervention. Myocardial enzymes [creatine kinase isoenzyme (CK-MB), troponin T (cTnT)], inflammation [high-sensitivity C-reactive protein (hs-CRP), interleukin-35 (IL-35)] and antioxidant indexes [total antioxidant capacity (T-AOC), superoxide dismutase (SOD), reduced glutathione (GSH)] were determined before and after treatment. Results The total treatment response rate of the observation group was significantly higher than that of the control group (94.59% vs 72.97%) (χ2=6.366, P=0.012). The levels of serum CK-MB, cTnT and hs-CRP in the observation group were significantly lower than those in the control group after treatment (t=8.279, 21.907, 9.703, all P=0.000), while levels of IL-35, T-AOC, SOD and GSH were significantly higher than those in the control group (t=10.194, 11.128, 15.539, 11.390, all P=0.000). There were 2 cases of mild fever in the observation group and 1 case of transient abdominal distension. Conclusions Puerarin injection is safe and effective in the treatment of VMC. It can significantly inhibit inflammation and improve the antioxidant capacity. Key words: Viral myocarditis; Puerarin; Antioxidant